Hyaluronan-mediated motility receptor (HMMR), also known as RHAMM (Receptor for Hyaluronan Mediated Motility) is a
protein which in humans is encoded by the HMMRgene.[5] RHAMM recently has been also designated CD168 (
cluster of differentiation 168).
Function
RHAMM was originally discovered as a soluble protein that altered migratory cell behavior and bound to
hyaluronan.[6] RHAMM is less well studied than the main hyaluronan (HA) receptor,
CD44. In contrast to CD44 and other cell-surface receptors which contain the classical membrane spanning domain and signal sequence for secretion from the
endoplasmic reticulum /
Golgi complex, RHAMM does not contain a membrane spanning domain nor does the mRNA transcript contain a signal sequence. RHAMM is localized inside the cell and is unconventionally exported to the cell surface in response to certain defined stimuli such as wounding and cytokines including TGF-β.[7] The precise unconventional export mechanism for transporting RHAMM to the extracellular space is still unclear but may involve transport channels or proteins, flippase activity, or exocytosis, similar to other non-conventionally exported cell surface proteins such as BFGF1,2 and epimorphin.[8]
Intracellularly, RHAMM associates with
microtubules and, working with
BRCA1 and
BARD1, plays a role in the regulation of mitosis,[8][9][10] and in maintaining mitotic spindle integrity.[11] RHAMM also binds directly with ERK1 and forms complexes with ERK1,2 and MEK1,[11] suggesting a role as a scaffold protein that targets these MAP kinases to the nucleus.[12]
Extracellularly, RHAMM associates with CD44, and upon binding to
hyaluronan, activates intracellular signaling pathways, mainly the MAPK pathway via ERK1,2 activation[13] Variants of RHAMM caused by
alternative splicing have been observed, and alternative start codon usage has been proposed in mice and directly observed in humans.[5]
Clinical significance
RHAMM is over expressed in
breast cancer and its expression in
triple negative and
HER2 subtypes is associated with poor outcome.[14]Alternatively spliced forms of RHAMM may be up regulated in some tumor types, promoting tumor progression.[15] The presence of breast tumor cell subsets with high RHAMM expression is associated with reduced metastasis free survival[16] and mediates migration, transformation, and metastatic spread of the triple negative human BCa cell line
MDA-MB-231.[17]
Elevated levels of RHAMM and
hyaluronan are associated with the likelihood of undergoing biochemical failure in intermediate risk prostate cancer patients.[18] RHAMM is also one of 3
biomarkers associated with aggressiveness in a multivariate analysis of human prostate tumors[19] and elevated levels of RHAMM are associated with both
androgen deprivation therapy and
castration resistant disease.[20] RHAMM has also been identified as one of 4 gene products identified in circulating tumor cells in patients with
lung adenocarcinoma.[21]
While RHAMM has been less studied than CD44 in the process of
cancer metastasis, it is likely just as important in this process and can act in concert with, or independently of CD44 to promote cell motility. Increased RHAMM expression is correlated with metastases in colorectal cancer, among others.[22] Mechanistically, RHAMM has been shown to promote cell motility through a number of different pathways. As with CD44, RHAMM can promote
focal adhesion turnover by controlling
focal adhesion kinase (FAK)
phosphorylation and cooperating with the α4β1 and α5β1
integrins.[23] RHAMM also activates a number of downstream kinases including enhancing the intensity and sustaining the duration of
ERK1 /
ERK2 activation through the
map kinase (MAPK) pathway, pp60 (
c-src), and the downstream targets of
rho kinase (ROK).[24] Finally, once a metastatic lesion has been established, RHAMM can cooperate with CD44 to promote
angiogenesis by promoting migration of neighboring
endothelial cells towards the tumor.[25]
^Turley EA (Oct 1982). "Purification of a hyaluronate-binding protein fraction that modifies cell social behavior". Biochemical and Biophysical Research Communications. 108 (3): 1016–1024.
doi:
10.1016/0006-291X(82)92101-5.
PMID6185115.
^Li H, Guo L, Li J, Liu N, Liu J (Oct 2000). "Alternative splicing of RHAMM gene in chinese gastric cancers and its in vitro regulation". Zhonghua Yi Xue Yi Chuan Xue Za Zhi = Zhonghua Yixue Yichuanxue Zazhi = Chinese Journal of Medical Genetics (in Chinese). 17 (5): 343–347.
PMID11024216.
Dawson SJ, White LA (May 1992). "Treatment of Haemophilus aphrophilus endocarditis with ciprofloxacin". The Journal of Infection. 24 (3): 317–320.
doi:
10.1016/S0163-4453(05)80037-4.
PMID1602151.
Spicer AP, Roller ML, Camper SA, McPherson JD, Wasmuth JJ, Hakim S, Wang C, Turley EA, McDonald JA (Nov 1995). "The human and mouse receptors for hyaluronan-mediated motility, RHAMM, genes (HMMR) map to human chromosome 5q33.2-qter and mouse chromosome 11". Genomics. 30 (1): 115–117.
doi:
10.1006/geno.1995.0022.
PMID8595891.
Wang C, Entwistle J, Hou G, Li Q, Turley EA (Oct 1996). "The characterization of a human RHAMM cDNA: conservation of the hyaluronan-binding domains". Gene. 174 (2): 299–306.
doi:
10.1016/0378-1119(96)00080-7.
PMID8890751.
Assmann V, Marshall JF, Fieber C, Hofmann M, Hart IR (Jun 1998). "The human hyaluronan receptor RHAMM is expressed as an intracellular protein in breast cancer cells". Journal of Cell Science. 111 (12): 1685–1694.
doi:
10.1242/jcs.111.12.1685.
PMID9601098.
Pilarski LM, Pruski E, Wizniak J, Paine D, Seeberger K, Mant MJ, Brown CB, Belch AR (May 1999). "Potential role for hyaluronan and the hyaluronan receptor RHAMM in mobilization and trafficking of hematopoietic progenitor cells". Blood. 93 (9): 2918–2927.
doi:
10.1182/blood.V93.9.2918.
PMID10216086.
Assmann V, Jenkinson D, Marshall JF, Hart IR (Nov 1999). "The intracellular hyaluronan receptor RHAMM/IHABP interacts with microtubules and actin filaments". Journal of Cell Science. 112 (22): 3943–3954.
doi:
10.1242/jcs.112.22.3943.
PMID10547355.
Lynn BD, Li X, Cattini PA, Nagy JI (Jun 2001). "Sequence, protein expression and extracellular-regulated kinase association of the hyaladherin RHAMM (receptor for hyaluronan mediated motility) in PC12 cells". Neuroscience Letters. 306 (1–2): 49–52.
doi:
10.1016/S0304-3940(01)01870-5.
PMID11403955.
S2CID38778150.
Lynn BD, Turley EA, Nagy JI (Jul 2001). "Subcellular distribution, calmodulin interaction, and mitochondrial association of the hyaluronan-binding protein RHAMM in rat brain". Journal of Neuroscience Research. 65 (1): 6–16.
doi:
10.1002/jnr.1122.
PMID11433424.
S2CID23843138.
Rein DT, Roehrig K, Schöndorf T, Lazar A, Fleisch M, Niederacher D, Bender HG, Dall P (Mar 2003). "Expression of the hyaluronan receptor RHAMM in endometrial carcinomas suggests a role in tumour progression and metastasis". Journal of Cancer Research and Clinical Oncology. 129 (3): 161–164.
doi:
10.1007/s00432-003-0415-0.
PMID12712331.
S2CID22224158.